BOT/BAL

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  

BOT/BAL
Feb 26, 2025, 09:26 | Blog
New translational insights on immune activation in refractory gastric cancer presented at AACRIO25 - Agenus
Agenus shared a post on LinkedIn: "Yesterday at AACRIO25, we presented new translational insights demonstrating…
Feb 16, 2025, 15:08 | Opinion
Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer
Garo Armen, PhD, a philanthropist and biotech leader, made the following address during the Second…
Jan 30, 2025, 05:52 | Blog
David Tougeron: Great results of the BOT/BAL combination in mCRC
David Tougeron, President of the FFCD Scientific Council, shared a post on LinkedIn: "Great results…
Jan 30, 2025, 04:40 | Insight
Breelyn Wilky: Promising outcomes for immune cold sarcomas with BOT/BAL
Breelyn Wilky, Director of Sarcoma Medical Oncology at University of Colorado Anschutz Medical Campus, shared…
Jan 23, 2025, 12:00 | Blog
Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer
Agenus shared on LinkedIn: “Today, we announced new data highlighting BOT/BAL across multiple lines of…
Nov 13, 2024, 15:07 | Blog
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
Agenus: Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus has announced its third-quarter…
Jul 19, 2024, 02:00 | Blog
I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan
"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…
Jul 18, 2024, 15:20 | Drugs
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…
Jun 28, 2024, 15:58 | Insight
Updates on BOT/BAL from ESMOGI24
ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…
Jun 28, 2024, 13:48 | Insight
Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24
Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…
Jun 28, 2024, 13:41 | Insight
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Agenus shared on their X page: "New data from the NEST clinical trial was presented…
Jun 28, 2024, 13:09 | Insight
Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC
Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…
Jun 28, 2024, 13:00 | Insight
Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer
Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…
Apr 22, 2024, 20:02 | Blog
Pashtoon Kasi: We underestimate how quickly immunotherapy works
Pashtoon Kasi, Director Colon Cancer Research and Director Precision Medicine Research for Liquid Biopsies at…
Apr 17, 2024, 17:16 | Insight
Rafeh Naqash: Fantastic discussion on biomarker testing and precison oncology
Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine, replied to the post of Rafeh…
Apr 13, 2024, 15:11 | Insight
Pashtoon Kasi: BOT/BAL we are at our 12+ patients with MSS colorectal cancer within weeks
Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine, shared a post on X/Twitter: ''We have…
Mar 26, 2024, 15:02 | Insight
Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks
Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine shared on LinkedIn: "We…
Feb 14, 2024, 14:59 | Blog
Yelena Janjigian is leading the investigator-initiated trial of the First Novel Combination of MiNK's Allogeneic Cell Therapy with Agenus' BOT/BAL
Today MiNK Therapeutics released an announcement of the First Refractory Gastric Cancer Patient Dosed in…
Oct 29, 2023, 03:34 | Drugs
Steven O'Day: The research we shared underscores BOT’s broad potential utility across multiple advanced solid tumors
Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "It was an exciting…
Oct 23, 2023, 15:23 | Drugs
Pashtoon Kasi: So excited to move the field forward with novel therapies for patients with pMMR/MSS Colorectal Cancer
Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital, shared on his Twitter:…
Oct 17, 2023, 01:38 | Drugs
Pashtoon Kasi: Our work on the use of BOT/BAL in the neoadjuvant setting for patients with advanced colon and rectal cancer
Quoting Pashtoon Kasi, Director of Colon Cancer Research at the Weill Cornell Medicine, on X/Twitter:…
All: 21 Posts: 1 - 100
Special Coverage